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ABSTRACT
OBJECTIVES
To quantify post-colonoscopy colorectal cancer 
(PCCRC) rates in England by using recent World 
Endoscopy Organisation guidelines, compare 
incidence among colonoscopy providers, and explore 
associated factors that could benefit from quality 
improvement initiatives.
DESIGN
Population based cohort study.
SETTING
National Health Service in England between 2005 and 
2013.
POPULATION
All people undergoing colonoscopy and subsequently 
diagnosed as having colorectal cancer up to three 
years after their investigation (PCCRC-3yr).
MAIN OUTCOME MEASURES
National trends in incidence of PCCRC (within 
6-36 months of colonoscopy), univariable and 
multivariable analyses to explore factors associated 
with occurrence, and funnel plots to measure variation 
among providers.
RESULTS
The overall unadjusted PCCRC-3yr rate was 7.4% 
(9317/126 152), which decreased from 9.0% in 
2005 to 6.5% in 2013 (P<0.01). Rates were lower for 
colonoscopies performed under the NHS bowel cancer 
screening programme (593/16 640, 3.6%), while they 
were higher for those conducted by non-NHS providers 
(187/2009, 9.3%). Rates were higher in women, in 
older age groups, and in people with inflammatory 
bowel disease or diverticular disease, in those 
with higher comorbidity scores, and in people with 
previous cancers. Substantial variation in rates among 
colonoscopy providers remained after adjustment for 
case mix.
CONCLUSIONS
Wide variation exists in PCCRC-3yr rates across 
NHS colonoscopy providers in England. The lowest 
incidence was seen in colonoscopies performed under 
the NHS bowel cancer screening programme. Quality 
improvement initiatives are needed to address this 
variation in rates and prevent colorectal cancer by 
enabling earlier diagnosis, removing premalignant 
polyps, and therefore improving outcomes.
Introduction
Colorectal cancer is a major public health problem 
in the United Kingdom. Each year, more than 40 000 
new patients are diagnosed as having the disease 
and there are around 16 000 deaths.1 International 
comparisons have revealed that the survival rate of 
patients with colorectal cancer in the UK lags behind 
that attained by many of our economic neighbours. 
This finding is largely because of a high mortality rate 
soon after diagnosis, particularly among older people. 
The best survival rates are observed in patients who are 
diagnosed at an early stage. Therefore, outcomes can 
be improved by optimising the diagnostic process.
Colonoscopy is the main test for diagnosing 
colorectal cancer. This procedure also has the potential 
to prevent the disease by removing precancerous 
lesions, and so it is an important tool to help improve 
outcomes.2 Unfortunately, the test is not 100% 
accurate and cancers can appear within months or 
years after a colonoscopy that is negative for cancer. 
The World Endoscopy Organisation defines these cases 
as post-colonoscopy colorectal cancers (PCCRCs).3 
Evidence suggests that up to 700 patients are 
diagnosed as having PCCRCs each year in the English 
National Health Service (NHS).4 Therefore, reducing 
the incidence of these cancers is vital.
Colonoscopy services in the NHS are under pressure. 
Currently, over 650 000 colonoscopies are undertaken 
each year, but demand is growing substantially and 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Post-colonoscopy colorectal cancer (PCCRC) is a key indicator for the quality of 
a colonoscopy service, but information on its incidence has not been routinely 
available
Previous studies have used different approaches that make benchmarking and 
comparison of rates among providers unreliable
The World Endoscopy Organisation has recently produced standardised methods 
to calculate rates so that comparisons can be made among institutions and 
jurisdictions
WHAT THIS STUDY ADDS
This study used World Endoscopy Organisation methods and found wide 
variation in PCCRC rates within three years of investigation among colonoscopy 
providers in England
Rates declined from 9.0% for colonoscopies performed in 2005 to 6.5% for those 
performed in 2013 (P<0.01)
The English NHS bowel cancer screening programme rates were much lower 
(3.6%) than those found for independent colonoscopy providers (9.3%)
By reducing the national PCCRC-3yr rate to an aspirational target of up to 3.6%, 
many cancers could be prevented or diagnosed at an earlier stage
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there is concern that the workforce needed to meet 
this demand is insufficient. Although major efforts 
have been made to ensure the NHS delivers high 
quality colonoscopy services, for example, the Joint 
Advisory Group on Gastrointestinal Endoscopy (JAG) 
accreditation scheme, not all providers have been 
mandated to participate. As a result, there is the 
potential for variation in the quality of colonoscopy 
services across the country; unless this variation is 
quantified, it cannot be addressed.
The British Society of Gastroenterology has proposed 
that PCCRC rates should be used as a benchmark for 
colonoscopy quality.5 Recently, the World Endoscopy 
Organisation6 provided methods to calculate rates so 
that comparisons can be made among institutions and 
jurisdictions. Our study aimed to apply these methods to 
compare PCCRC rates within three years of colonoscopy 
(PCCRC-3yr) among all providers, and to quantify varia-
tion in colonoscopy quality across the English NHS.
Methods
Study population
We obtained study data from the UK Colorectal Cancer 
Intelligence Hub’s colorectal cancer data repository 
(CORECT-R), in which routine cancer datasets are 
linked to provide a rich resource of population based 
data.7 Our study population consisted of people who 
had undergone a colonoscopy in the English NHS 
between 1 January 2005 and 31 December 2013 
and who subsequently developed colorectal cancer 
(International Classification of Diseases, 10th revision 
(ICD10) codes C18-20). We used linked inpatient 
and outpatient Hospital Episode Statistics (HES) data 
(OPCS4 codes H20-22), English NHS bowel cancer 
screening programme (BCSP), and National Cancer 
Registration and Analysis Service datasets available 
within the resource. The BCSP offers screening 
(through an initial guaiac based faecal occult blood 
test to determine eligibility for colonoscopy; soon to 
be replaced by a faecal immunochemical test) every 
two years to women and men aged 60-74. After age 74, 
people can request additional screening tests.8
The colonoscopy data included all procedures per-
formed by NHS providers, private patients treated at 
NHS centres, and procedures performed by independent 
providers paid for by the NHS. We excluded tumours 
that involve the appendix (ICD10 C181) or those with 
a neuroendocrine, lymphoma, squamous, or melanoma 
morphology. Only adenocarcinoma subtypes were 
included because they are the main focus for detecting 
and preventing cancer after removal of serrated and 
adenomatous polyps. We limited our cohort to those 
with colorectal cancer that was diagnosed within 
three years of colonoscopy and with data extracted 
for analysis at colonoscopy level. The cohort was then 
split into three groups for analysis based on the year of 
colonoscopy: 2005-07, 2008-10, and 2011-13.
PCCRC-3yr rate calculation
Methods produced by the World Endoscopy 
Organisation were used to calculate the PCCRC-3yr 
rate.6 We categorised colonoscopies into positive 
and negative tests according to whether a cancer 
was diagnosed within six months of the test. When a 
colorectal cancer occurred within the first six months 
after a colonoscopy, this was a true positive test; when 
a colorectal cancer appeared between six and 36 
months after a colonoscopy, this was a false negative 
test. We defined cancers as detected cancers if they 
were preceded by a true positive colonoscopy and as 
a PCCRC-3yr if they were preceded by a false negative 
colonoscopy. This 6-36 month window for defining a 
PCCRC-3yr rate is advocated by the World Endoscopy 
Organisation so that institutions and jurisdictions can 
be compared by using the same metric. The definition 
does not require the index test to be negative for 
adenomas.
We appreciate that the terms false negative and true 
positive normally depend on a gold standard, which 
does not exist for the diagnosis of colorectal cancer 
and its precursors. Therefore, we assume that the gold 
standard is cancer diagnosed within three years of a 
colonoscopy. Some cancers that appear after a negative 
colonoscopy might be new, rapidly growing cancers or 
cancers arising from premalignant polyps. Thus, in 
this instance we use the term gold standard to refer 
to the potential of colonoscopy to detect or prevent 
cancers that will present within three years after the 
colonoscopy.
Some people in the cohort underwent multiple 
colonoscopies. For these people, we only included 
true positive and false negative colonoscopies that 
were recorded closest to the time of diagnosis, which 
is in accordance with World Endoscopy Organisation 
methods.
Cohort characteristics
We identified colonoscopies undertaken within 
the BCSP, but the indication for the procedure was 
otherwise unknown. However, other patient level 
data were available and so we investigated relevant 
factors that might increase the risk of PCCRC. These 
data included age at diagnosis and colonoscopy 
stratified into age bands (≤60, 61-70, 71-80, and >80). 
We used these cut-off points because at the time of 
the study bowel cancer screening invitations began 
at age 60. Other variables were sex, socioeconomic 
status (based on the income domain of the index of 
multiple deprivation 2007),9 and a comorbidity score 
based on diagnostic HES codes in the year before 
cancer diagnosis (subdivided into 0, 1, 2, and ≥3). 
The comorbidity score was the Charlson score,10 with 
the exception of malignancy because all patients had 
a diagnosis of colorectal cancer. We included several 
cancer related variables: stage, classified as stage I-IV, 
or unknown when data were missing; and colonic 
location of the tumour defined as caecum, right sided 
(ascending colon to transverse colon; C18.0-18.4), left 
sided (splenic flexure to rectosigmoid junction; C18.5-
18.7 and C19.0), rectal (C20), or unspecified when 
no location was given (C18.8-18.9). We also recorded 
when cancers were diagnosed through an “emergency 
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presentation” because this method of referral is 
associated with worse outcomes for colorectal cancer 
in the UK.11
Additionally, we identified people with a previous 
HES coded diagnosis of inflammatory bowel disease, 
Crohn’s disease, ulcerative colitis (ICD10 codes K50-
51), or diverticular disease (ICD10 code K57). We 
also identified people with a previous diagnosis of 
colorectal cancer or previous colonoscopy, which 
was any colonoscopy performed before the test 
that diagnosed the colorectal cancer or the false 
negative test when the cancer was not diagnosed by 
colonoscopy.
Statistical analyses
We calculated the proportion of people with cancer 
who had true positive and false negative colonoscopies, 
and the PCCRC-3yr rate for each three year group 
according to World Endoscopy Organisation methods. 
We identified the healthcare provider that performed 
each colonoscopy by using the unique five digit codes 
recorded in HES data and from the screening centre 
in the BCSP. NHS organisations change over time 
(for example, hospital mergers), therefore historical 
organisations were mapped to current providers, as 
they existed on 1 January 2018. Some providers had 
low workloads, which made comparison of PCCRC-
3yr rates with other providers potentially unreliable.12 
Therefore, we performed an a priori power calculation 
to determine the minimum number of cases that 
might be needed to detect an important difference 
among providers. We used a PCCRC-3yr rate of 7.5% 
for this calculation based on a previous rate of 8.6% 
from a study that covered an earlier time period4 and 
an assumption that this rate would have reduced. 
A doubling of this rate to 15% was deemed to be 
unacceptably high. Based on this number and 80% 
power at the 0.05 significance level, a colonoscopy 
provider would need to detect 96 cancers in any given 
time period for there to be sufficient statistical power to 
be labelled as a significant outlier.
We calculated the PCCRC-3yr rate for each year 
in the study period, and used χ2 for trend as a 
significance test. Additional analyses were undertaken 
for subgroups: patients with inflammatory bowel 
disease; people who had colonoscopies as part of the 
BCSP; and a “non-surveillance” group that excluded 
people who had colonoscopies within the BCSP and 
those with a diagnosis of inflammatory bowel disease. 
We estimated the number of people with PCCRC if the 
unadjusted rate for each year in the study period was 
reduced to the 75th centile as a potential benchmark 
for a minimum standard, and then at the rate achieved 
by the BCSP as an aspirational target. This would 
indicate the potential number of cancers that could 
be diagnosed earlier or prevented if the overall rate is 
improved to these levels.
We explored the change in PCCRC rate over time for 
each provider by grouping each unit in the earliest 
cohort (2005-07) into fifths based on the PCCRC-3yr 
rate. Similar fifths were then produced for the 2011-13 
period and the change in fifths was compared for each 
colonoscopy provider.
We built multilevel, logistic regression models to 
determine factors associated with the occurrence of 
PCCRC-3yr. The models were structured to reflect that 
people could have undergone multiple colonoscopies, 
with the person fitted as a random effect. The dependent 
variable was the occurrence of PCCRC-3yr. Exploratory 
variables were year of colonoscopy, age group at 
colonoscopy, sex, index of multiple deprivation 
income category (fifths), comorbidity score, and a 
previous HES coded diagnosis of inflammatory bowel 
disease or diverticular disease, previous colorectal 
cancer, and previous colonoscopy; additionally, 
whether the colonoscopy was performed within the 
BCSP, independent sector, or a non-BCSP service.
We produced unadjusted and risk adjusted funnel 
plots by using these models and the Spiegelhalter 
method13 to quantify variation in the rate of PCCRC-
3yr for each colonoscopy provider in each time 
period. Funnel plots are a useful graphical display 
for institutional variation; they are constructed as a 
scatterplot with superimposed control limits, which 
represent two and three standard deviations from the 
mean. The smaller the sample size, the wider the control 
limits.14 Providers who fall outside the control limits 
have PCCRC rates that are statistically significantly 
different from the national rate, independently of 
the case mix factors adjusted for and colonoscopy 
workload, and so indicate unwarranted variation. We 
also created unadjusted and risk adjusted histograms 
to show the PCCRC-3yr rate for each colonoscopy 
provider in each of the three time periods. Non-
modifiable risk factors were used for these models: 
year of colonoscopy, age group at colonoscopy, sex, 
index of multiple deprivation income category (fifths), 
comorbidity score, previous HES coded diagnosis of 
inflammatory bowel disease or diverticular disease, 
previous colorectal cancer, and previous colonoscopy; 
additionally whether the colonoscopy was undertaken 
within the BCSP or independent sector. All analyses 
were performed using Stata version 15 (StataCorp, 
College Station, TX).
Patient and public involvement
A patient and public group was involved at the design 
stage of the study. Results have been reported back 
to the group. The group will be involved in preparing 
dissemination materials which will be fed back to 
the colonoscopy providers and released through 
the national charities Bowel Cancer UK and Cancer 
Research UK.
Results
From an estimated population in England of over 
55 million in 2016,15 our study included 126 152 
colonoscopies in 121 402 people who were diagnosed 
as having colorectal cancer within three years of their 
investigation. In this population, 9317 (7.4%) were 
classified as PCCRC-3yr. There was a statistically 
significant reduction in the PCCRC-3yr rate from 9.0% 
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for colonoscopies performed in 2005 to 6.5% for 
those performed in 2013 (P<0.01) (fig 1). The PCCRC-
3yr rate in people with inflammatory bowel disease 
was 38.3% for colonoscopies performed in 2005 and 
35.5% for those performed in 2013 (P=0.24). For the 
BCSP colonoscopies, the rate increased from 2.7% in 
2005 to 3.6% in 2013, but did not reach statistical 
significance (P=0.06). For colonoscopies performed 
in people with non-inflammatory bowel disease and 
those that were not conducted within the BCSP, there 
was a significant reduction in the rate from 8.2% 
in 2005 to 7.3% in 2013 (P<0.01). Most providers 
stayed within the same fifth of the PCCRC-3yr rate 
in the 2005-07 and 2011-13 groups (supplementary 
table S3).
Table 1 shows the proportion of detected cancers and 
the PCCRC-3yr rate in relation to the characteristics of 
the population and the colonoscopies they underwent. 
The PCCRC-3yr rate was higher after colonoscopies 
performed in the earlier study periods; in women; 
among people with a higher comorbidity score; in 
those with a previous HES code for inflammatory bowel 
disease or diverticular disease; in people with previous 
colorectal cancer; and with increasing numbers of 
previous colonoscopy tests. The PCCRC-3yr rate was 
higher in the oldest age group than in the youngest age 
group. Additionally, the rate was much lower in those 
who had colonoscopies as part of the BCSP (PCCRC-
3yr rate 3.6%) than in those who had colonoscopies 
performed by independent providers outside of the 
NHS (9.3% across the entire study period). The PCCRC-
3yr rate was higher in people with early (stage I), late 
(stage IV), and unknown stage cancers, and in those 
with cancer in the proximal colon. Significantly more 
people were diagnosed as having PCCRC-3yr after an 
emergency presentation, which is associated with 
poorer outcomes.
After multivariable analysis for the factors which can 
be assessed at the time of colonoscopy, which excludes 
stage and colonic location, these associations were 
sustained and all remained statistically significant 
(P<0.01) (table 2).
Institutional comparison
A total of 135, 139, and 140 colonoscopy providers 
were operating in the English NHS during the time 
periods 2005-07, 2008-10, and 2011-13, respectively. 
Figure 2 and figure 3 show unadjusted and adjusted 
institutional comparisons for each of the time periods 
(see also table 3).
Across each time period we found significant 
variation in unadjusted and adjusted PCCRC-3yr rates. 
In 2011-13, unadjusted rates ranged from 3.2% to 
16.4%, and adjusted rates ranged from 3.2% to 12.8%. 
Supplementary table 1 shows the centiles for the range 
of unadjusted PCCRC-3yr rates in 2011-13; the best 
performing 5% had an unadjusted PCCRC-3yr rate of 
4% and the worst performing 5% had a rate of 10.4%.
In the unadjusted funnel plot for the years 2011-13, 
two providers were outside the upper 99.8% control 
limit, with 11 providers outside the upper 95% control 
limit, which indicates higher PCCRC-3yr rates than 
expected. In contrast, seven providers had rates below 
the lower 95% control limit, which suggests they had 
lower PCCRC-3yr rates than expected. No providers 
were below the lower 99.8% control limit. After risk 
adjustment for the non-modifiable factors identified 
above, one provider was above the upper 99.8% 
control limit, with 10 providers outside the upper 95% 
control limit. In contrast, there were five providers with 
rates below the lower 95% control limit. No providers 
had rates below the 99.8% control limit. Figure 2, 
figure 3, and table 3 show the results for the years 
2005-07, 2008-10, and 2011-13.
We estimated the potential benefit of higher quality 
colonoscopy by calculating the reduction in PCCRC-3yr 
if a 6.7% rate, which was found in the 2011-13 cohort, 
was reduced across the study period. Supplementary 
figure S1 shows the results of these estimates. Overall, 
if we reduced the rate to 5.5% or 3.6% as achieved 
in the BCSP, for the entire study period there would 
potentially be 168 or 435 fewer patients with PCCRC 
each year, respectively.
Discussion
Principal findings
Our study uses World Endoscopy Organisation 
methods and robust population based data across 
the entire English NHS. Although PCCRC-3yr rates 
are declining, in the most recent cohort the rate was 
6.5%. We found a much lower PCCRC-3yr rate for 
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Fig 1 | Trends in unadjusted rates of post-colonoscopy colorectal cancer within 
three years of investigation (PCCRC-3yr) for each year of colonoscopy. Top panel: all 
colonoscopies, “non-surveillance,” and UK bowel cancer screening programme (BCSP). 
Bottom panel: colonoscopies in people with an admission code for inflammatory bowel 
disease. “Non-surveillance” colonoscopies are those in people not diagnosed as having 
inflammatory bowel disease and those not performed within the BCSP
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colonoscopies performed as part of the BCSP (3.6%). If 
this aspirational rate had been achieved for the entire 
study period, more than 3900 patients with colorectal 
cancer could have been diagnosed earlier or received 
preventative treatment.
Although PCCRC-3yr rates fell during each 
successive time period, we still observed major 
discrepancies among providers, which persisted after 
adjustment for associated risk factors. This variation 
needs to be minimised to increase early diagnosis rates 
Table 1 | Detected cancers and PCCRC-3yr rate in relation to characteristics of study population and type of colonoscopy. 
Values are No (%) unless stated otherwise
Characteristic
Colonoscopies with colorectal cancer diagnosed within  
three years PCCRC-3yr rate (%)
Total True positive False negative
Total 126 152 116 835 9317 7.4
Year of colonoscopy
2005-07 31 336 28 711 (25) 2625 (28) 8.4
2008-10 44 165 40 856 (35) 3309 (36) 7.5
2011-13 50 651 47 268 (40) 3383 (36) 6.7
Age at colonoscopy
≤60 22 185 20 731 (18) 1454 (16) 6.6
61-70 38 521 36 153 (31) 2368 (25) 6.1
71-80 42 833 39 479 (34) 3354 (36) 7.8
>80 22 613 20 472 (18) 2141 (23) 9.5
Sex
Male 73 459 68 344 (58) 5115 (55) 7.0
Female 52 693 48 491 (42) 4202 (45) 8.0
IMD income category
Most affluent 27 180 25 169 (22) 2011 (22) 7.4
2 28 331 26 246 (22) 2085 (22) 7.4
3 26 479 24 533 (21) 1946 (21) 7.3
4 23 857 22 078 (19) 1779 (19) 7.5
Least affluent 20 305 18 809 (16) 1496 (16) 7.4
Charlson comorbidity score
0 93 684 87 738 (75) 5946 (64) 6.3
1 21 576 19 590 (17) 1986 (21) 9.2
2 6438 5715 (5) 723 (8) 11.2
≥3 4454 3792 (3) 662 (7) 14.9
Inflammatory bowel disease
No 123 428 108 893 (98) 8348 (90) 6.8
Yes 2724 1756 (2) 968 (10) 35.5
Diverticular disease
No 94 437 88 813 (76) 5624 (60) 6.0
Yes 31 715 28 022 (24) 3693 (40) 11.6
Previous colorectal cancer
No 124 513 115 708 (99) 8805 (95) 7.1
Yes 1639 1127 (1) 512 (5) 31.2
Previous colonoscopy
No 105 972 100 541 (86) 5431 (58) 5.1
Yes 20 180 16 294 (14) 3886 (42) 19.3
Colonoscopy within BCSP
No 109 512 100 788 (86) 8724 (94) 8.0
Yes 16 640 16 047 (14) 593 (6) 3.6
Colonoscopy by independent provider
No 124 143 115 013 (98) 9130 (98) 7.4
Yes 2009 1822 (2) 187 (2) 9.3
Cancer characteristics
Stage:
 I 21 474 19 597 (17) 1877 (20) 8.7
 II 34 605 32 613 (28) 1992 (21) 5.8
 III 33 240 31 186 (27) 2054 (22) 6.2
 IV 13 564 12 252 (10) 1312 (14) 9.7
 Unknown 23 269 21 187 (18) 2082 (22) 8.9
Colonic location:
 Rectum 31 492 29 496 (25) 1996 (21) 6.3
 Distal colon 40 783 38 450 (33) 2333 (25) 5.7
 Proximal colon 27 383 25 143 (22) 2240 (24) 8.2
 Caecum 20 978 19 057 (16) 1921 (21) 9.2
 Colon NOS 5516 4689 (4) 827 (9) 15.0
BCSP=English NHS bowel cancer screening programme; IMD=index of multiple deprivation; NOS=not otherwise specified; PCCRC-3yr=post-colonoscopy 
colorectal cancer within three years of colonoscopy.
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and improve colorectal cancer outcomes. PCCRC-3yr 
rates for colonoscopies undertaken by independent 
providers were higher than those reported for 
NHS providers. These independent providers are 
increasingly being used to meet the rising demand for 
colonoscopies.
We found a lower incidence of PCCRC-3yr for 
colonoscopies performed as part of the BCSP. All 
BCSP colonoscopies are performed within JAG 
accredited screening centres by colonoscopists who 
have undergone an additional accreditation process.16 
BCSP colonoscopies are of a high standard, with high 
adenoma detection and caecal intubation rates.16 
Screening colonoscopists adhere to strict performance 
criteria, including an unadjusted caecal intubation 
rate greater than 92% and an adenoma detection rate 
greater than 40%. Adenoma detection rate correlates 
with PCCRC, therefore it is reasonable to assume 
that the high quality of colonoscopies in the BCSP 
contributes to the reduced PCCRC-3yr rates reported in 
this study.17 This important finding shows that when 
standards are applied rigorously, quality can improve. 
Another reason for the decrease in PCCRC-3yr could be 
because of improvements in endoscopic equipment, 
including adjuncts to improve detection. A recent 
randomised study showed increased adenoma number 
detection with newer generation endoscopes.18
In contrast to the BCSP, we found a higher PCCRC 
rate after colonoscopies undertaken in the inde-
pendent sector. In recent years there has been a 
marked increase in demand for colonoscopies in the 
UK and NHS services have not been able to deliver the 
number of investigations required, principally because 
of workforce constraints. Therefore, the independent 
sector has been used to relieve the backlog of NHS 
waiting list procedures and we anticipate that they will 
have generally undertaken “low risk” colonoscopies 
for which the chance of finding cancer is reduced. 
Table 2 | Odds of developing PCCRC-3yr in relation to characteristics of study population and type of colonoscopy
Characteristic
Unadjusted Adjusted
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Year of colonoscopy
2005-07 1 — 1 —
2008-10 0.89 (0.84 to 0.93) <0.01 0.86 (0.82 to 0.91) <0.01
2011-13 0.78 (0.74 to 0.83) <0.01 0.70 (0.66 to 0.74) <0.01
Age at colonoscopy
≤60 1 — 1 —
61-70 0.93 (0.87 to 1.00) 0.05 1.02 (0.94 to 1.09) 0.67
71-80 1.21 (1.14 to 1.29) <0.01 1.02 (0.96 to 1.10) 0.50
>80 1.49 (1.39 to 1.60) <0.01 1.17 (1.09 to 1.27) <0.01
Sex
Male 1 — 1 —
Female 1.16 (1.11 to 1.21) <0.01 1.15 (1.10 to 1.20) <0.01
IMD income category
Most affluent 1 — 1 —
2 0.99 (0.93 to 1.06) 0.86 0.98 (0.91 to 1.04) 0.50
3 0.99 (0.93 to 1.06) 0.83 0.98 (0.91 to 1.05) 0.52
4 1.01 (0.94 to (1.08) 0.97 0.97 (0.91 to 1.04) 0.44
Least affluent 1.00 (0.93 to 1.07) 0.9 0.93 (0.86 to 1.00) 0.27
Charlson comorbidity score
0 1 — 1 —
1 1.50 (1.42 to 1.58) <0.01 1.36 (1.28 to 1.44) <0.01
2 1.87 (1.72 to 2.03) <0.01 1.62 (1.48 to 1.76) <0.01
≥3 2.58 (2.36 to 2.81) <0.01 2.17 (1.98 to 2.38) <0.01
Inflammatory bowel disease
No 1 — 1 —
Yes 7.60 (7.00 to 8.24) <0.01 4.93 (4.50 to 5.40) <0.01
Diverticular disease
No 1 — 1 —
Yes 2.08 (1.99 to 2.17) <0.01 1.88 (1.79 to 1.97) <0.01
Colonoscopy within BCSP
No 1 — 1 —
Yes 0.4 (0.39 to 0.46) <0.01 0.68 (0.62 to 0.74) <0.01
Colonoscopy by independent provider
No 1 — 1 —
Yes 1.29 (1.11 to 1.51) <0.01 1.63 (1.39 to 1.91) <0.01
Previous colorectal cancer
No 1 — 1 —
Yes 5.95 (5.35 to 6.62) <0.01 2.24 (2.00 to 2.52) <0.01
Previous colonoscopy
No 1 — 1 —
Yes 4.41 (4.22 to 4.62) <0.01 3.29 (3.13 to 3.46) <0.01
BCSP=English NHS bowel cancer screening programme; IMD=index of multiple deprivation; PCCRC-3yr=post-colonoscopy colorectal cancer within three 
years of colonoscopy.
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We suggest that people at higher risk of developing 
PCCRC (for example, those with inflammatory bowel 
disease, genetic conditions predisposing them to 
colorectal cancer, or large polyps) will have remained 
under NHS care and so the higher rates of PCCRC in 
the independent sector might be a cause for concern; 
however, more detailed data are required to fully 
quantify the risks. Additional research into provider 
characteristics that influence colonoscopy outcomes 
would provide valuable information on how to 
optimise NHS colonoscopy services. For example, do 
outcomes differ among providers who do and do not 
deliver JAG19 authorised colonoscopy training? While 
we were not able to perform these analyses in our 
study, further studies using new data sources, such as 
the new National Endoscopy Database and the Private 
Healthcare Information Network, are proposed to 
deliver this additional information.
We found that it is important to determine risk factors 
and define high risk groups so that endoscopists are 
more aware of the potential for PCCRC. Our data support 
established risk factors, including increasing age at 
colonoscopy,20 female sex,20 21 more comorbidities,22 
diverticular disease,22 23 and inflammatory bowel 
disease.24 Previous colorectal cancer and multiple 
previous colonoscopies also had strong associations 
with PCCRC rates. Some of these factors might be 
associated with incomplete colonoscopy, which is 
a strong predictor of PCCRC risk.20 In this event, it is 
important that a timely repeat procedure or alternative 
test is performed, such as cross sectional imaging if 
clinically appropriate.
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Fig 2 | Unadjusted variation in rates of post-colonoscopy colorectal cancer within three years of investigation (PCCRC-3yr) by provider for 2005-07, 
2008-10, and 2011-13. In funnel plots each dot represents an individual colonoscopy provider. Dashed lines represent 95% and 99.8% control 
limits outside national PCCRC-3yr rate (solid line). X axis is number of detected cancers plus PCCRC-3yr cancers diagnosed in the period. Yellow dots 
indicate providers who diagnosed less than 96 cancers in the given period. Hollow dots represent independent colonoscopy providers
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The PCCRC-3yr rate for people with inflammatory 
bowel disease was over three times that of the 
entire study cohort, an association that has been 
reported in previous studies.24 25 Despite a sig-
nificant improvement in rates in people without 
inflammatory bowel disease, the PCCRC-3yr rate in 
people with inflammatory bowel disease remained 
constant throughout our study period (P=0.24). 
Societal guidelines now advocate surveillance on 
an annual basis for some people with inflammatory 
bowel disease who are at high risk. While these UK 
guidelines were published in 2010,26 they do not seem 
to have impacted on the PCCRC-3yr rate (although 
the data are relatively immature, with colonoscopy 
data from only three years after their introduction). 
Additional work to monitor guideline implementation 
and impact on PCCRC rates is warranted, not least 
because colorectal cancer is a serious complication 
of inflammatory bowel disease, and surveillance 
colonoscopy is a considerable burden for patients and 
healthcare providers. In the context of surveillance, 
detection of some patients with PCCRC could reflect 
the success of the procedure in identifying colorectal 
cancer early. Therefore, with more colonoscopies 
being performed, an increase in PCCRC rates will be 
inevitable, although it is unlikely that this accounts 
entirely for the increased PCCRC rates found in 
our study. Despite guidelines for surveillance,26 
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Fig 3 | Adjusted variation in rates of post-colonoscopy colorectal cancer within three years of investigation (PCCRC-3yr) by provider for 2005-07, 
2008-10, and 2011-13. In funnel plots each dot represents an individual colonoscopy provider. Dashed lines represent 95% and 99.8% control 
limits outside national PCCRC-3yr rate (solid line). X axis is number of detected cancers plus PCCRC-3yr cancers diagnosed in the period. Adjusted for 
non-modifiable risk factors: year of colonoscopy, age group at colonoscopy, sex, index of multiple deprivation income category (fifths), comorbidity 
score, previous Hospital Episode Statistics coded diagnosis of inflammatory bowel disease or diverticular disease, previous colorectal cancer, 
previous colonoscopy, and whether the colonoscopy was within English NHS bowel cancer screening programme or by independent provider. Yellow 
dots indicate providers who diagnosed less than 96 cancers in the given period. Hollow dots represent independent colonoscopy providers
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unfortunately these are poorly adhered to.27 Quality 
measures will need to be addressed, which should be 
the focus of future studies.
Strengths and limitations
Previous studies have shown the rates of PCCRC are 
highly sensitive to the method used for calculation and 
the quality of the data to which that method is applied.4 
It is vital to have consistent methods to enable reliable 
benchmarking and comparison of rates. Such an 
approach would identify what might be possible, but 
also would highlight areas of underperformance that 
could benefit from quality improvement interventions. 
Our study used standardised methods from the World 
Endoscopy Organisation to calculate PCCRC-3yr rates 
from a population based dataset that includes all 
cancers diagnosed in England and all colonoscopies 
associated with cancer undertaken as part of the 
screening programme or to investigate symptoms. 
It is not feasible to perform these analyses on single 
centre or local datasets because there is often a time 
lag of several years between the negative test and 
subsequent pathology. Furthermore, people might be 
diagnosed as having cancer in a different centre to 
where the colonoscopy was performed, and therefore, 
not be captured using local data. National datasets 
circumvent this problem to a large extent.
The study is potentially limited because the data are 
from routinely collected clinical codes, and therefore 
are subject to ascertainment bias. We believe this risk 
to be low because previous validation studies have 
shown 96% accuracy for routine data collected in 
HES and over 99% accuracy in the National Cancer 
Registry and Analysis Service.28 29 The dataset is taken 
from an NHS administrative dataset that is used for 
reimbursement and so we expect the numbers of 
procedures not included in this dataset to be extremely 
low; however, this possibility cannot be discounted 
entirely. In addition, there will be a small number 
of colonoscopies undertaken outside of the NHS by 
independent providers.
Because we based the study on administrative 
data, there were important potential causal factors 
that we could not consider in these analyses. For 
example, details on whether lesions were incompletely 
resected,30 the presence of large or multiple adenomas, 
the extent of bowel preparation, failure to book or 
non-compliance with recommendations for repeat 
shorter interval testing are all relevant. Unfortunately, 
such data are not routinely collected in English 
population datasets. Service level factors exist at each 
institution that could account for some of the variation 
seen. Additionally, some institutions perform more 
procedures with a higher risk of colorectal cancer and 
therefore PCCRC, such as inflammatory bowel disease 
surveillance and surveillance after the endoscopic 
removal of large polyps or early cancers. These 
variables should be considered in any future research 
into the cause of PCCRC.
Conclusions and policy implications
Overall, there has been a sustained improvement 
in the PCCRC-3yr rate in England. This probably 
reflects the national initiatives put in place to 
improve the quality of colonoscopy in England since 
2003, overseen initially by the National Endoscopy 
Team,31 and subsequently by the JAG and the 
British Society of Gastroenterology. For example, 
most endoscopy services in England are now 
participating in JAG accreditation, which involves 
achieving certain standards for service and training, 
including monitoring performance of colonoscopy 
and implementing interventions to address poor 
performance. Additionally, there has been a national 
colonoscopy training programme since 2003.31 
There is some evidence that these interventions have 
improved colonoscopy performance,32-34 particularly 
completion of the procedure and appropriate 
adenoma detection rates, but further work is required 
to confirm their impact. It is also noteworthy that 
providers outside the NHS, which have only recently 
engaged in JAG accreditation,35 had a higher overall 
rate of PCCRC-3yr than NHS providers. It will be 
important to determine if gaining JAG accreditation 
helps to close the gap in PCCRC rates between NHS 
and non-NHS providers. A recent study from Canada, 
where no such quality improvement initiatives have 
been mandated, found no reduction in the PCCRC-3yr 
rate in those aged 50-74 between 1996 and 2010.36
Benchmarks need to be set for minimum 
acceptable standards and aspirational targets. These 
benchmarks have not been defined for PCCRC-3yr 
rates. The 25% centile from the range of unadjusted 
PCCRC-3yr rates was 5.5% and the BCSP rate was 
3.6%; these levels would be reasonable benchmarks 
for a minimum standard and aspirational target, 
respectively. Reduced rates could be achievable 
because colorectal cancer detected under the BCSP 
are smaller lesions, and therefore more likely to be 
missed.37 Furthermore, rates were falling up to the 
Table 3 | Institutional variation in risk adjusted and unadjusted PCCRC-3yr rate for each 
time period. Values are numbers unless stated otherwise
PCCRC-3yr rate 2005-07 2008-10 2011-13
Adjusted
Highest PCCRC-3yr rate (%)* 16.3 14.4 12.8
Lowest PCCRC-3yr rate (%)* 3.4 3.5 3.2
Colonoscopy providers 135 139 140
Above 99.8% CL 1 1 1
Above 95% CL 7 8 10
Within 95% CL 120 125 124
Below 95% CL 6 5 5
Below 99.8% CL 1 0 0
Unadjusted
Highest PCCRC-3yr rate (%)* 19.9 17.6 16.4
Lowest PCCRC-3yr rate (%)* 2.0 3.2 3.2
Colonoscopy providers 135 139 140
Above 99.8% CL 5 5 2
Above 95% CL 13 12 11
Within 95% CL 111 116 120
Below 95% CL 4 6 7
Below 99.8% CL 2 0 0
CL=control limit; PCCRC-3yr=post-colonoscopy colorectal cancer within three years of colonoscopy.
*Providers that detected at least 96 cancers.
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end of 2013; if this trend has continued, recent rates 
are already likely to be lower.
We need to define causal factors for PCCRC to 
target people most at risk and implement quality 
improvement interventions. A large study of PCCRC 
risk factors found that in a cohort of over 1000 patients 
with PCCRC, 46% had at least one factor that might 
have been avoidable.20 In the UK, a recent cohort study 
by Anderson and colleagues found that approximately 
70% of PCCRCs might be because of avoidable factors, 
such as missed or incompletely resected lesions at 
previous colonoscopy.38 These results suggest that 
despite the improvements over time observed in our 
study, further reduction in PCCRC-3yr rates is possible.
Serious potential implications exist after a failed 
test, not limited to colorectal cancer investigations. 
After a false negative test patients and healthcare 
professionals might ignore significant symptoms, and 
delay or avoid repeat investigation. False negative 
tests also represent a missed opportunity to prevent a 
future cancer, and the patient might have been spared 
the consequences of the diagnosis. Potential costs 
are incurred for patients and healthcare funders and 
providers of a false negative test: a second colonoscopy 
or other test might be required; treatment might have to 
be given for cancer that could have been unnecessary; 
and cancers are probably more advanced and might 
have metastasised. Finally, there is the psychological 
impact of a delayed diagnosis; even if the prognosis is 
unaffected, patients and their relatives will probably 
believe their outlook is worse because of the delay.
There is robust evidence that endoscopic 
screening prevents colorectal cancer,39 and the 
removal of adenomatous polyps reduces death from 
colorectal cancer.40 However, by improving the 
quality of colonoscopy there is the potential for over 
diagnosis41 because polyps will be detected that 
prompt surveillance in some people who will not die 
from colorectal cancer. Reassuringly, recent studies 
have shown a low risk of colorectal cancer in those 
with small polyps found at their index test.42 43 As a 
result of this evidence, surveillance guidelines might 
change to try and reduce the number of unnecessary 
colonoscopies.
In conclusion, we suggest that the PCCRC-3yr 
rate is a key performance indicator of the quality of 
colonoscopy. A minimum standard of up to 5.5% and 
an aspirational target of up to 3.6% could be applied as 
quality standards. Substantial unwarranted variation 
in PCCRC-3yr rates exists among colonoscopy 
providers in England. PCCRC is largely avoidable and 
targeted measures are required to reduce rates for all 
colonoscopy providers, improve earlier detection, and 
reduce mortality rates from this preventable disease.
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